Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation

Julie M. Vose, Thomas Matthew Habermann, Myron S. Czuczman, Pier Luigi Zinzani, Craig B. Reeder, Joseph M. Tuscano, Izidore S. Lossos, Ju Li, Dennis Pietronigro, Thomas Elmer Witzig

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Patients with aggressive non-Hodgkin lymphoma (NHL) who relapse after autologous stem cell transplantation (ASCT) have a poor prognosis. Additional therapy is often poorly tolerated, and new treatment modalities are needed. This efficacy and safety study was a retrospective analysis of two phase II trials (NHL-002 and NHL-003) that studied single-agent lenalidomide in patients with relapsed/refractory aggressive NHL with prior (n = 87) compared with no prior ASCT (n = 179). The overall response rate in the ASCT group was 39% [14% complete response (CR)], including 29% in patients with diffuse large B-cell lymphoma, 63% in mantle cell lymphoma, and 60% in transformed lymphoma. The timing of transplant relative to receiving lenalidomide had no effect on outcomes. Median progression-free survival for the ASCT group was 3·7 months (16·9 months for patients in CR; 7·3 months for partial responders) at a median 12·5-month follow-up. Median response duration was 7·9 months. Regardless of prior ASCT, lenalidomide monotherapy was efficacious in heavily pretreated patients with aggressive, relapsed/refractory NHL, with a safety profile that was consistent with prior studies of single-agent lenalidomide.

Original languageEnglish (US)
Pages (from-to)639-647
Number of pages9
JournalBritish Journal of Haematology
Volume162
Issue number5
DOIs
StatePublished - Sep 2013

Fingerprint

Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Safety
Mantle-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Disease-Free Survival
Lymphoma
lenalidomide
Transplants
Recurrence
Therapeutics

Keywords

  • Autologous stem cell transplantation
  • Lenalidomide
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. / Vose, Julie M.; Habermann, Thomas Matthew; Czuczman, Myron S.; Zinzani, Pier Luigi; Reeder, Craig B.; Tuscano, Joseph M.; Lossos, Izidore S.; Li, Ju; Pietronigro, Dennis; Witzig, Thomas Elmer.

In: British Journal of Haematology, Vol. 162, No. 5, 09.2013, p. 639-647.

Research output: Contribution to journalArticle

Vose, Julie M. ; Habermann, Thomas Matthew ; Czuczman, Myron S. ; Zinzani, Pier Luigi ; Reeder, Craig B. ; Tuscano, Joseph M. ; Lossos, Izidore S. ; Li, Ju ; Pietronigro, Dennis ; Witzig, Thomas Elmer. / Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. In: British Journal of Haematology. 2013 ; Vol. 162, No. 5. pp. 639-647.
@article{1a79ab3d4c134ef1b3a31ccb90dafe88,
title = "Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation",
abstract = "Patients with aggressive non-Hodgkin lymphoma (NHL) who relapse after autologous stem cell transplantation (ASCT) have a poor prognosis. Additional therapy is often poorly tolerated, and new treatment modalities are needed. This efficacy and safety study was a retrospective analysis of two phase II trials (NHL-002 and NHL-003) that studied single-agent lenalidomide in patients with relapsed/refractory aggressive NHL with prior (n = 87) compared with no prior ASCT (n = 179). The overall response rate in the ASCT group was 39{\%} [14{\%} complete response (CR)], including 29{\%} in patients with diffuse large B-cell lymphoma, 63{\%} in mantle cell lymphoma, and 60{\%} in transformed lymphoma. The timing of transplant relative to receiving lenalidomide had no effect on outcomes. Median progression-free survival for the ASCT group was 3·7 months (16·9 months for patients in CR; 7·3 months for partial responders) at a median 12·5-month follow-up. Median response duration was 7·9 months. Regardless of prior ASCT, lenalidomide monotherapy was efficacious in heavily pretreated patients with aggressive, relapsed/refractory NHL, with a safety profile that was consistent with prior studies of single-agent lenalidomide.",
keywords = "Autologous stem cell transplantation, Lenalidomide, Non-Hodgkin lymphoma",
author = "Vose, {Julie M.} and Habermann, {Thomas Matthew} and Czuczman, {Myron S.} and Zinzani, {Pier Luigi} and Reeder, {Craig B.} and Tuscano, {Joseph M.} and Lossos, {Izidore S.} and Ju Li and Dennis Pietronigro and Witzig, {Thomas Elmer}",
year = "2013",
month = "9",
doi = "10.1111/bjh.12449",
language = "English (US)",
volume = "162",
pages = "639--647",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation

AU - Vose, Julie M.

AU - Habermann, Thomas Matthew

AU - Czuczman, Myron S.

AU - Zinzani, Pier Luigi

AU - Reeder, Craig B.

AU - Tuscano, Joseph M.

AU - Lossos, Izidore S.

AU - Li, Ju

AU - Pietronigro, Dennis

AU - Witzig, Thomas Elmer

PY - 2013/9

Y1 - 2013/9

N2 - Patients with aggressive non-Hodgkin lymphoma (NHL) who relapse after autologous stem cell transplantation (ASCT) have a poor prognosis. Additional therapy is often poorly tolerated, and new treatment modalities are needed. This efficacy and safety study was a retrospective analysis of two phase II trials (NHL-002 and NHL-003) that studied single-agent lenalidomide in patients with relapsed/refractory aggressive NHL with prior (n = 87) compared with no prior ASCT (n = 179). The overall response rate in the ASCT group was 39% [14% complete response (CR)], including 29% in patients with diffuse large B-cell lymphoma, 63% in mantle cell lymphoma, and 60% in transformed lymphoma. The timing of transplant relative to receiving lenalidomide had no effect on outcomes. Median progression-free survival for the ASCT group was 3·7 months (16·9 months for patients in CR; 7·3 months for partial responders) at a median 12·5-month follow-up. Median response duration was 7·9 months. Regardless of prior ASCT, lenalidomide monotherapy was efficacious in heavily pretreated patients with aggressive, relapsed/refractory NHL, with a safety profile that was consistent with prior studies of single-agent lenalidomide.

AB - Patients with aggressive non-Hodgkin lymphoma (NHL) who relapse after autologous stem cell transplantation (ASCT) have a poor prognosis. Additional therapy is often poorly tolerated, and new treatment modalities are needed. This efficacy and safety study was a retrospective analysis of two phase II trials (NHL-002 and NHL-003) that studied single-agent lenalidomide in patients with relapsed/refractory aggressive NHL with prior (n = 87) compared with no prior ASCT (n = 179). The overall response rate in the ASCT group was 39% [14% complete response (CR)], including 29% in patients with diffuse large B-cell lymphoma, 63% in mantle cell lymphoma, and 60% in transformed lymphoma. The timing of transplant relative to receiving lenalidomide had no effect on outcomes. Median progression-free survival for the ASCT group was 3·7 months (16·9 months for patients in CR; 7·3 months for partial responders) at a median 12·5-month follow-up. Median response duration was 7·9 months. Regardless of prior ASCT, lenalidomide monotherapy was efficacious in heavily pretreated patients with aggressive, relapsed/refractory NHL, with a safety profile that was consistent with prior studies of single-agent lenalidomide.

KW - Autologous stem cell transplantation

KW - Lenalidomide

KW - Non-Hodgkin lymphoma

UR - http://www.scopus.com/inward/record.url?scp=84881664038&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881664038&partnerID=8YFLogxK

U2 - 10.1111/bjh.12449

DO - 10.1111/bjh.12449

M3 - Article

VL - 162

SP - 639

EP - 647

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -